These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30665421)

  • 1. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.
    Pechmann A; König K; Bernert G; Schachtrup K; Schara U; Schorling D; Schwersenz I; Stein S; Tassoni A; Vogt S; Walter MC; Lochmüller H; Kirschner J
    Orphanet J Rare Dis; 2019 Jan; 14(1):18. PubMed ID: 30665421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Steinbach M; Blaschek A; Baumann M; Baumgartner M; Becker B; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Küpper H; Johannsen J; Kamm C; Koch JC; Köhler C; Kölbel H; Kolzter K; von Moers A; Naegel S; Neuwirth C; Petri S; Rödiger A; Schimmel M; Schrank B; Schreiber G; Smitka M; Stadler C; Steiner E; Stögmann E; Trollmann R; Türk M; Weiler M; Stoltenburg C; Willichowsky E; Zeller D; Ziegler A; Lochmüller H; Kirschner J;
    J Neuromuscul Dis; 2023; 10(1):29-40. PubMed ID: 36565133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
    Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
    JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial.
    Schwartz O; Vill K; Pfaffenlehner M; Behrens M; Weiß C; Johannsen J; Friese J; Hahn A; Ziegler A; Illsinger S; Smitka M; von Moers A; Kölbel H; Schreiber G; Kaiser N; Wilichowski E; Flotats-Bastardas M; Husain RA; Baumann M; Köhler C; Trollmann R; Schwerin-Nagel A; Eisenkölbl A; Schimmel M; Fleger M; Kauffmann B; Wiegand G; Baumgartner M; Rauscher C; Cirak S; Gläser D; Bernert G; Hagenacker T; Goldbach S; Probst-Schendzielorz K; Lochmüller H; Müller-Felber W; Schara-Schmidt U; Walter MC; Kirschner J; Pechmann A;
    JAMA Pediatr; 2024 Jun; 178(6):540-547. PubMed ID: 38587854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design.
    Finkel RS; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Shieh PB; Tizzano E; Desguerre I; Quijano-Roy S; Saito K; Droege M; Dabbous O; Khan F; Renault L; Anderson FA; Servais L
    J Neuromuscul Dis; 2020; 7(2):145-152. PubMed ID: 32039859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A National Spinal Muscular Atrophy Registry for Real-World Evidence.
    Hodgkinson VL; Oskoui M; Lounsberry J; M'Dahoma S; Butler E; Campbell C; MacKenzie A; McMillan HJ; Simard L; Vajsar J; Brais B; Chapman KM; Chrestian N; Crone M; Dobrowolski P; Dojeiji S; Dowling JJ; Dupré N; Genge A; Gonorazky H; Hasal S; Izenberg A; Johnston W; Leung E; Lochmüller H; Mah JK; Marerro A; Massie R; McAdam L; McCormick A; Melanson M; Mezei MM; Nguyen CE; O'Connell C; O'Ferrall EK; Pfeffer G; Phan C; Plamondon S; Poulin C; Rodrigue X; Schellenberg KL; Selby K; Sheriko J; Shoesmith C; Smith G; Taillon M; Taylor S; Warman Chardon J; Worley S; Korngut L
    Can J Neurol Sci; 2020 Nov; 47(6):810-815. PubMed ID: 32493524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy-Protocol of a Controlled Mixed-Methods Study.
    Willems J; Farin-Glattacker E; Langer T
    Front Pediatr; 2021; 9():614512. PubMed ID: 34414138
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Nusinersen - Challenges Regarding the Indication for Children with SMA Type 1.
    Pechmann A; Baumann M; Bernert G; Flotats-Bastardas M; Gruber-Sedlmayr U; von der Hagen M; Hasselmann O; Hobbiebrunken E; Horber V; Johannsen J; Kellersmann A; Köhler C; von Moers A; Müller-Felber W; Plecko B; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stoltenburg C; Stüve B; Theophil M; Weiß C; Wiegand G; Wilichowski E; Winter B; Wittmann W; Schara U; Kirschner J
    J Neuromuscul Dis; 2020; 7(1):41-46. PubMed ID: 31744015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)].
    Ziegler A; Wilichowski E; Schara U; Hahn A; Müller-Felber W; Johannsen J; von der Hagen M; von Moers A; Stoltenburg C; Saffari A; Walter MC; Husain RA; Pechmann A; Köhler C; Horber V; Schwartz O; Kirschner J
    Nervenarzt; 2020 Jun; 91(6):518-529. PubMed ID: 32394004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy.
    Cattinari MG; de Lemus M; Tizzano E
    Orphanet J Rare Dis; 2024 Feb; 19(1):76. PubMed ID: 38373977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany.
    Leibrock B; Landfeldt E; Hussong J; Huelle T; Mattheus H; Thiele S; Walter MC; Zemlin M; Moehler E; Dillman U; Abner S; Flotats-Bastardas M
    Orphanet J Rare Dis; 2023 Feb; 18(1):32. PubMed ID: 36810103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
    Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
    BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2.
    Vill K; Tacke M; König A; Baumann M; Baumgartner M; Steinbach M; Bernert G; Blaschek A; Deschauer M; Flotats-Bastardas M; Friese J; Goldbach S; Gross M; Günther R; Hahn A; Hagenacker T; Hauser E; Horber V; Illsinger S; Johannsen J; Kamm C; Koch JC; Koelbel H; Koehler C; Kolzter K; Lochmüller H; Ludolph A; Mensch A; Meyer Zu Hoerste G; Mueller M; Mueller-Felber W; Neuwirth C; Petri S; Probst-Schendzielorz K; Pühringer M; Steinbach R; Schara-Schmidt U; Schimmel M; Schrank B; Schwartz O; Schlachter K; Schwerin-Nagel A; Schreiber G; Smitka M; Topakian R; Trollmann R; Tuerk M; Theophil M; Rauscher C; Vorgerd M; Walter MC; Weiler M; Weiss C; Wilichowski E; Wurster CD; Wunderlich G; Zeller D; Ziegler A; Kirschner J; Pechmann A;
    J Neurol; 2024 May; 271(5):2787-2797. PubMed ID: 38409538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-Reported Health-Related Quality of Life of Children with Spinal Muscular Atrophy: Preliminary Insights from a Nationwide Patient Registry in Germany.
    Landfeldt E; Leibrock B; Hussong J; Thiele S; Abner S; Walter MC; Moehler E; Zemlin M; Dillmann U; Flotats-Bastardas M
    J Neuromuscul Dis; 2024; 11(1):117-128. PubMed ID: 38108360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
    Paracha N; Hudson P; Mitchell S; Sutherland CS
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):69-89. PubMed ID: 34658008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.